INCA033989

Monoclonal antibody

Phase 3underway

Evidence outlook · registrational

Essential Thrombocythemia: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-06-15.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Essential Thrombocythemia
Phase 1 (3)
Other / comorbidity
NCT06034002 · Incyte Corporation
2023-12-04 – 2028-10-29 · Myeloproliferative Neoplasms
What this study did
NCT07448155 · Incyte Corporation
2026-03-19 – 2026-11-14 · Healthy Participants
What this study did

Competitive landscape

This drug's own stage for Essential Thrombocythemia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
INCA033989: this drugPhase 3Monoclonal antibodymutant calreticulin (mutCALR)not yet gradedNo reviewed efficacy summary in this indication
Ropeginterferon Alfa-2b (Besremi)ApprovedProtein / enzyme therapeuticType I interferon receptorPartial signal
NCT04285086: Durable modified ELN response at months 9 and 12: 39 (43%) of 91 ropeginterferon alfa-2b vs five (6%) of 83 anagrelide
BomedemstatPhase 3Small moleculeLSD1 (lysine-specific demethylase 1)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow INCA033989 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
February 2028 (1)
Phase 1Myeloproliferative NeoplasmsActive not recruiting
Est. primary completion 2028-02-29 · NCT05936359 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1Myeloproliferative NeoplasmsRecruiting
Est. primary completion 2028-10-29 · NCT06034002 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Phase 3Essential ThrombocythemiaRecruiting
Est. primary completion 2029-06-15 · NCT07623200 · CT.gov ↗
What to watch

See the full readout calendar ↗